FI972793L - Nebivololin käyttö antiaterogeenisenä aineena - Google Patents

Nebivololin käyttö antiaterogeenisenä aineena Download PDF

Info

Publication number
FI972793L
FI972793L FI972793A FI972793A FI972793L FI 972793 L FI972793 L FI 972793L FI 972793 A FI972793 A FI 972793A FI 972793 A FI972793 A FI 972793A FI 972793 L FI972793 L FI 972793L
Authority
FI
Finland
Prior art keywords
nebivolol
antiatherogenic
agent
antiatherogenic agent
Prior art date
Application number
FI972793A
Other languages
English (en)
Swedish (sv)
Other versions
FI118884B (fi
FI972793A0 (fi
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI972793A0 publication Critical patent/FI972793A0/fi
Publication of FI972793L publication Critical patent/FI972793L/fi
Application granted granted Critical
Publication of FI118884B publication Critical patent/FI118884B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
FI972793A 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena FI118884B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic
EP9505174 1995-12-21

Publications (3)

Publication Number Publication Date
FI972793A0 FI972793A0 (fi) 1997-06-27
FI972793L true FI972793L (fi) 1997-06-27
FI118884B FI118884B (fi) 2008-04-30

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972793A FI118884B (fi) 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena

Country Status (20)

Country Link
US (2) US5874461A (fi)
EP (1) EP0801564B1 (fi)
JP (1) JPH10511655A (fi)
KR (1) KR100264348B1 (fi)
CN (1) CN1167418C (fi)
AT (1) ATE214924T1 (fi)
AU (1) AU700364B2 (fi)
CA (1) CA2207333C (fi)
CZ (1) CZ287513B6 (fi)
DE (1) DE69526120T2 (fi)
DK (1) DK0801564T3 (fi)
ES (1) ES2176354T3 (fi)
FI (1) FI118884B (fi)
HU (1) HU226208B1 (fi)
NO (1) NO315687B1 (fi)
NZ (1) NZ298074A (fi)
PT (1) PT801564E (fi)
SI (1) SI0801564T1 (fi)
SK (1) SK282144B6 (fi)
WO (1) WO1996019987A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176354T3 (es) * 1994-12-28 2002-12-01 Janssen Pharmaceutica Nv Uso de nebivolol como agente anti-aterogenico.
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (sl) 2001-01-26 2006-10-31 Schering Corp Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DK1429756T3 (da) 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US8604222B2 (en) 2004-07-30 2013-12-10 Forest Laboratories Holdings Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
HUE033304T2 (en) 2005-06-01 2017-11-28 Bioelectron Tech Corp Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CN102257131A (zh) * 2008-12-19 2011-11-23 先灵公司 用于哺乳动物细胞培养的给料添加剂及使用方法
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TW201615194A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 氨苯蝶啶藥物應用於癌症治療
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
ES2176354T3 (es) * 1994-12-28 2002-12-01 Janssen Pharmaceutica Nv Uso de nebivolol como agente anti-aterogenico.

Also Published As

Publication number Publication date
US5874461A (en) 1999-02-23
CZ191997A3 (cs) 1999-01-13
ES2176354T3 (es) 2002-12-01
SI0801564T1 (en) 2002-08-31
EP0801564A1 (en) 1997-10-22
JPH10511655A (ja) 1998-11-10
AU4347796A (en) 1996-07-19
SK85697A3 (en) 2000-04-10
FI118884B (fi) 2008-04-30
PT801564E (pt) 2002-09-30
WO1996019987A1 (en) 1996-07-04
MX9704669A (es) 1997-09-30
HUT77927A (hu) 1998-11-30
KR100264348B1 (ko) 2000-08-16
NO972980L (no) 1997-06-26
SK282144B6 (sk) 2001-11-06
CA2207333A1 (en) 1996-07-04
US6075046A (en) 2000-06-13
CZ287513B6 (en) 2000-12-13
CN1171739A (zh) 1998-01-28
AU700364B2 (en) 1999-01-07
ATE214924T1 (de) 2002-04-15
HU226208B1 (en) 2008-06-30
CA2207333C (en) 2006-10-17
DE69526120T2 (de) 2002-11-28
FI972793A0 (fi) 1997-06-27
NO315687B1 (no) 2003-10-13
EP0801564B1 (en) 2002-03-27
NO972980D0 (no) 1997-06-26
NZ298074A (en) 2001-01-26
CN1167418C (zh) 2004-09-22
DE69526120D1 (de) 2002-05-02
DK0801564T3 (da) 2002-07-15

Similar Documents

Publication Publication Date Title
FI972793L (fi) Nebivololin käyttö antiaterogeenisenä aineena
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
FI963278L (fi) Verihiutaleen tuotantoa edistävä aine
DE69513300D1 (de) Bestimmungsverfahren
BR9509868A (pt) Fralda
DE69529223D1 (de) Prüfverfahren
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
ATE201305T1 (de) Gewürzmittel
IS4321A (is) Nýjar díalkoxý-pýridínýl-bensimidasólafleiður
BR9507892A (pt) Novos derivados de diamino-metilideno
DE69524487D1 (de) Sterilisiervorrichtung
KR960023412U (ko) 로터리 압축기의 압축장치
FI20041236L (fi) Silmänpainetta alentava aine
BR9509295A (pt) Escareador
BR9509877A (pt) Novos derivados de pirimidinilóxi-e piridimidinilamino- etilfenil-dioxolano
ITMI950222A0 (it) Tessuto
FI943921L (fi) Vapaan trypsinogeeni-2:n määritys
FR2726766B1 (fr) Sterilisateur
BR9508669A (pt) Novos derivados de taizoloÚ3,2-a¾quinolina e naftirina
KR960020013U (ko) 굳은 살 제거구
KR960020187U (ko) 저주파 전침기
PT101483A (pt) Instrumento cirurgico - porta/passa - fios
KR960004995U (ko) 높이조절이 가능한 곽티슈의 케이스
UA644S (uk) Мікро-еом широкого призначення
SE9403002D0 (sv) Desinfektionsvätska

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118884

Country of ref document: FI

MA Patent expired